SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 1536.
  • 2
    Nomura A. Stomach cancer. In: SchottenfeldD,FraumeniJF, eds. Cancer epidemiology and prevention,2nd edn. New York: Oxford University Press, 1996: 70724.
  • 3
    Wu AH,Yang D,Pike MC. A meta-analysis of soyfoods and risk of stomach cancer: the problem of potential confounders. Cancer Epidemiol Biomarkers Prev 2000; 9: 10518.
  • 4
    Kato I,Tominaga S,Matsumoto K. A prospective study of stomach cancer among a rural Japanese population: a 6-year survey. Jpn J Cancer Res 1992; 83: 56875.
  • 5
    Terry PD,Lagergren J,Wolk A,Steineck G,Nyren O. Dietary intake of heterocyclic amines and cancers of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 2003; 12: 9404.
  • 6
    Kono S,Hirohata T. Nutrition and stomach cancer. Cancer Causes Control 1996; 7: 4155.
  • 7
    Correa P,Fontham E,Pickle LW,Chen V,Lin YP,Haenszel W. Dietary determinants of gastric cancer in south Louisiana inhabitants. J Natl Cancer Inst 1985; 75: 64554.
  • 8
    Nagao M,Fujita Y,Wakabayashi K,Sugimura T. Ultimate forms of mutagenic and carcinogenic heterocyclic amines produced by pyrolysis. Biochem Biophys Res Commun 1983; 114: 62631.
  • 9
    Sugimura T. Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat Res 1985; 150: 3341.
  • 10
    Vineis P,Caporaso N. Tobacco and cancer: epidemiology and the laboratory. Environ Health Perspect 1995; 103: 15660.
  • 11
    Bjeldanes LF,Morris MM,Timourian H,Hatch FT. Effects of meat composition and cooking conditions on mutagen formation in fried ground beef. J Agric Food Chem 1983; 31: 1821.
  • 12
    Snyderwine EG. Mammary gland carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats: possible mechanisms. Cancer Lett 1999; 143: 21115.
  • 13
    Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506–507: 6577.
  • 14
    Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 2002; 3: 1930.
  • 15
    Hein DW,Doll MA,Fretland AJ,Leff MA,Webb SJ,Xiao GH. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 2942.
  • 16
    Hein DW,Doll MA,Rustan TD,Gray K,Feng Y,Ferguson RJ,Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14: 16338.
  • 17
    Hein DW,Rustan TD,Ferguson RJ,Doll MA,Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamides by wild type and mutant recombinant human NAT1 and NAT2 acetyltransferase. Arch Toxicol 1994; 68: 12933.
  • 18
    Sanderson S,Salanti G,Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic huge review and evidence synthesis. Am J Epidemiol 2007; 166: 74151.
  • 19
    He LJ,Yu YM,Qiao F,Liu JS,Sun XF,Jiang LL. Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk. World J Gastroenterol 2005; 11: 426871.
  • 20
    Ochs-Balcom HM,Wiesner G,Elston RC. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol 2007; 166: 24654.
  • 21
    Hamasaki T,Inatomi H,Katoh T,Aono H,Ikuyama T,Muratani T,Matsumoto T. N-Acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol 2003; 10: 16773.
  • 22
    Seow A,Zhao B,Poh WT,Teh M,Eng P,Wang YT,Tan WC,Lee EJ,Lee HP. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcinogenesis 1999; 20: 187781.
  • 23
    Lan Q,Rothman N,Chow WH,Lissowska J,Doll MA,Xiao GH,Zatonski W,Hein DW. No apparent association between NAT1 and NAT2 genotypes and risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 3846.
  • 24
    Hein DW,Doll MA,Rustan TD,Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of seven specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55: 35316.
  • 25
    Zang Y,Doll MA,Zhao S,States JC,Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007; 28: 166571.
  • 26
    The Korean Nutrition Society. Recommended dietary allowance for Koreans, 7th revision. Seoul: Jung-Ang Publishing, 2000.
  • 27
    Willett W,Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986; 124: 1727.
  • 28
    Hartman TJ,Woodson K,Stolzenberg-Solomon R,Virtamo J,Selhub J,Barrett MJ,Albanes D. Association of the B-vitamins pyridoxal 5′-phosphate (B6), B(12), and folate with lung cancer risk in older men. Am J Epidemiol 2001; 153: 68894.
  • 29
    Zhang SM,Willett WC,Selhub J,Hunter DJ,Giovannucci EL,Holmes MD,Colditz GA,Hankinson SE. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95: 37380.
  • 30
    Kaaks R,Tuyns AJ,Haelterman M,Riboli E. Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer 1998; 78: 41520.
  • 31
    Knekt P,Reunanen A,Takkunen H,Aromaa A,Heliovaara M,Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 37982.
  • 32
    Nomura AM,Stemmermann GN,Chyou PH. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res 1995; 86: 91623.
  • 33
    Akiba S,Neriishi K,Blot WJ,Kabuto M,Stevens RG,Kato H,Land CE. Serum ferritin and stomach cancer risk among a Japanese population. Cancer 1991; 67: 170712.
  • 34
    Broitman SA,Velez H,Vitale JJ. A possible role of iron deficiency in gastric cancer in Colombia. Adv Exp Med Biol 1981; 135: 15581.
  • 35
    Herbert V,Shaw S,Jayatilleke E,Stopler-Kasdan T. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin. Stem Cells 1994; 12: 289303.
  • 36
    Stevens RG,Jones DY,Micozzi MS,Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319: 104752.
  • 37
    Stevens RG,Graubard BI,Micozzi MS,Neriishi K,Blumberg SB. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994; 56: 3649.
  • 38
    Kune S,Kune GA,Watson LF. Case-control study of dietary etiological factors: the Melbourne colorectal cancer study. Nutr Cancer 1987; 9: 2142.
  • 39
    Jenab M,Ferrari P,Slimani N,Norat T,Casagrande C,Overad K,Olsen A,Stripp C,Tjonneland A,Boutron-Ruault MC,Clavel-Chapelon F,Kesse E, et al. Association of nut and seed intake with colorectal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2004; 13: 1595603.
  • 40
    Milner JA. Mechanisms by which garlic and allyl sulphur compounds suppress cancinogen bioactivation. Adv Exp Med Biol 2001; 492: 6981.
  • 41
    Cellini L,Di Campli E,Masulli M,Di Bartolomeo S,Allocati N. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol 1996; 13: 2737.
  • 42
    Ito LS,Inoue M,Tajima K,Yamamura Y,Kodera Y,Hirose K,Takezaki T,Hamajima N,Kuroishi T,Tominaga S. Dietary factors and the risk of gastric cancer among Japanese women: a comparison between the differentiated and non-differentiated subtypes. Ann Epidemiol 2003; 13: 2431.
  • 43
    Hansson LE,Nyren O,Bergstrom R,Wolk A,Lindgren A,Baron J,Adami HO. Diet and risk of gastric cancer: a population-based case-control study in Sweden. Int J Cancer 1993; 55: 1819.
  • 44
    Ahn YO. Diet and stomach cancer in Korea. Int J Cancer 1997; 10: 79.
  • 45
    Wang HJ,Murphy PA. Isoflavone content in commercial soybean foods. J Agric Food Chem 1994; 42: 166673.
  • 46
    Cai Q,Wei H. Effect of dietary genistein on antioxidant enzyme activities in SENCAR mice. Nutr Cancer 1996; 25: 17.
  • 47
    Fotsis T,Pepper M,Adlercreutz H,Fleischmann G,Hase T,Montesano R,Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1993; 125: 7907.
  • 48
    Markovits J,Linassier C,Fosse P,Couprie J,Pierre J,Jacquemin-Sablon A,Saucier JM,Le Pecq JB,Larsen AK. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989; 49: 511117.
  • 49
    Akiyama T,Ishida J,Nakagawa S,Ogawara H,Watanabe S,Itoh N,Shiyba M,Fukami Y. Genistein, a specific inhibitor of tyrosine-specific kinase. J Biol Chem 1987; 25: 559295.
  • 50
    Yanagihara K,Ito A,Toge T,Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53: 581521.
  • 51
    AngCYW,LiuKS,HuangYW, eds. Asian foods science and technology. New York: Technomic Pub Co, 1999.
  • 52
    Messina MJ,Persky V,Setchell KD,Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 11331.
  • 53
    Haenszel W,Kurihara M,Segi M,Lee RK. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst 1972; 49: 96988.
  • 54
    You WC,Blot WJ,Chang YS,Ershow AG,Yang ZT,An Q,Henderson B,Xu GW,Fraumeni JF,Wang TG. Diet and high risk of stomach cancer in Shandong, China. Cancer Res 1988; 48: 351823.
  • 55
    Haenszel W,Kurihara M,Locke FB,Shimuzu K,Segi M. Stomach cancer in Japan. J Natl Cancer Inst 1976; 56: 26574.
  • 56
    World Cancer Research Fund American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington: AICR, 1997: 14875.
  • 57
    Nagai M,Hashimoto T,Yanagawa H,Yokoyama H,Minowa M. Relationship of diet to the incidence of esophageal and stomach cancer in Japan. Nutr Cancer 1982; 3: 25768.
  • 58
    Seel DJ,Kawabata T,Nakamura M,Ishibashi T,Hamano M,Mashimo M,Shin SH,Sakamoto K,Jhee EC,Watanabe S. N-nitroso compounds in two nitrosated food products in southwest Korea. Food Chem Toxicol 1994; 32: 111723.
  • 59
    Okkels H,Sigsgaard T,Wolf H,Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6: 22531.
  • 60
    Brockmoller J,Cascorbi I,Kerb R,Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 391525.
  • 61
    Ambrosone CB,Freudenheim JL,Graham S,Marshall JR,Vena JE,Brasure JR,Michalek AM,Laughlin R,Nemoto T,Gillenwater KA,Shields PG. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276: 1494501.
  • 62
    Lee SY,Lee KA,Ki CS,Kwon OJ,Kim HJ,Chung MP,Suh GY,Kim JW. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 2002; 48: 7757.
  • 63
    Graf T,Broly F,Hoffmann F,Probst M,Meyer UA,Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43: 399403.
  • 64
    Lin HJ,Han CY,Lin BK,Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 12534.
  • 65
    Deguchi T,Mashimo M,Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265: 1275760.
  • 66
    Rothman N,Hayes RB,Bi W,Caporaso N,Broly F,Woosley RL,Yin S,Feng P,You X,Meyer UA. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993; 3: 2505.
  • 67
    Deloménie C,Sica L,Grant DM,Krishnamoorthy R,Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996; 6: 17785.
  • 68
    Boissy RJ,Watson MA,Umbach DM,Deakin M,Elder J,Strange RC,Bell DA. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer 2000; 87: 50711.
  • 69
    Boccia S,Sayed-Tabatabaei FA,Persiani R,Gianfagna F,Rausei S,Arzani D,La Greca A,D'Ugo D,La Torre G,van Duijn CM,Ricciardi G. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer 2007; 7: 206.
  • 70
    Al-Moundhri MS,Al-Kindi M,Al-Nabhani M,Al-Bahrani B,Burney IA,Al-Madhani A,Ganguly SS,Tanira M. NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. World J Gastroenterol 2007; 13: 2697702.
  • 71
    Ladero JM,Agundez JA,Olivera M,Lozano L,Rodriguez-Lescure A,Diaz-Rubio M,Benitez J. N-Acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol 2002; 58: 11518.
  • 72
    Gonzalez CA,Sala N,Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002; 100: 24960.
  • 73
    Osawa Y,Osawa KK,Miyaishi A,Higuchi M,Tsutou A,Matsumura S,Tabuchi Y,Tsubota N,Takahashi J. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 2007; 8: 1038.
  • 74
    Sillanpaa P,Kataja V,Eskelinen M,Kosma VM,Uusitupa M,Vainio H,Mitrunen K,Hirvonen A. Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women. Pharmacogenet Genomics 2005; 15: 74952.
  • 75
    Vineis P,Bartsch H,Caporaso N,Harrington AM,Kadlubar FF,Landi MT,Malaveille C,Shields PG,Skipper P,Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994; 369: 1546.
  • 76
    Gu J,Liang D,Wang Y,Lu C,Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 2005; 581: 97104.
  • 77
    Oyama T,Kawamoto T,Mizoue T,Yasumoto K,Kodama Y,Mitsudomi T. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 1997; 17: 57781.
  • 78
    Habalová V,Salagovic J,Kalina I,Stubna J. A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer. Neoplasma 2005; 52: 3648.